BB-205

BB-205 is a novel bispecific antibody-drug conjugate (ADC) designed to target two tumor-associated antigens: human epidermal growth factor receptor 2 (HER2) and hepatocyte growth factor receptor (c-Met). Developed by Bright Biologics, the molecule is engineered using humanized anti-HER2 and anti-c-Met VHH fragments fused with a human IgG1 Fc region. It is conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) via a cathepsin-cleavable valine-citrulline (vc) linker. BB-205 is intended to address tumor heterogeneity and potential escape mechanisms by dual-targeting antigens that are often co-expressed or separately expressed in various solid tumors, including lung, pancreatic, and kidney cancers. In preclinical studies, BB-205 demonstrated superior cytotoxicity and higher internalization rates compared to single-target reference ADCs in dual-expressing cancer cell lines. In vivo xenograft models for pancreatic and lung cancer showed significant tumor growth inhibition and high rates of tumor-free survival following treatment.